Phase II Trial To Evaluate The Potential For Helical Tomotherapy IMRT To Improve Bladder Cancer Chemoradiation
Patients opting for bladder conservation in Ottawa are currently treated using
intra-arterial cisplatin and concurrent radiotherapy using 3D-Conformal radiotherapy. It
has been recently reported that while combination chemotherapy with local therapy (surgery
or radiation) does modestly increase survival, greater toxicity results. As a precursor to
the integration of gemcitabine in the standard chemotherapy regimen at our centre, the
current clinical trial is designed to determine if a novel approach to the delivery of
intensity modulated radiotherapy (IMRT), namely Helical Tomotherapy, will decrease the
toxicity of standard chemoradiation. Chemoradiation will be administered as follows: 3
courses Intra-Arterial Cisplatin 90mg/m2 every 3 weeks and radical radiation delivered as
IMRT for a total dose of 60 Gy in 30 daily fractions of 2 Gy per day M-F starting day 15.
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Acute GI toxicity
Libni Eapen, MD
Study Director
Ottawa Hospital Research Institute
Canada: Health Canada
2005407-01H
NCT00350688
November 2005
April 2010
Name | Location |
---|